What Is an Allograft? Definition, Uses, and Procedure

An allograft is tissue transplanted from one person to another. The donor and recipient are both human but genetically different, which distinguishes an allograft from an autograft (tissue moved from one part of your own body to another) and a xenograft (tissue taken from a different species, such as cow or pig bone). Allografts are used across dozens of surgical specialties, from orthopedics to burn care to eye surgery, and the science behind how they are collected, processed, and integrated into a recipient’s body is more involved than most patients realize before being offered one.

How Allografts Fit Into the Graft Family

Surgeons choose among several graft categories depending on what a patient needs. An autograft uses your own tissue, often harvested from a nearby site during the same operation. Because the tissue is yours, your immune system accepts it readily, and it carries living cells that jump-start healing. The trade-off is a second surgical wound and the pain that comes with it. A xenograft comes from another species; bovine and porcine bone grafts are common in dental and maxillofacial surgery, for instance.¹ An allograft sits between these two: it is human tissue, so it is structurally and biologically similar to what it replaces, but it comes from a donor, which means the recipient’s immune system may react to it.

Most allografts come from cadaveric donors, meaning tissue is recovered after the donor’s death. In some cases, living donors contribute tissue, particularly skin from first-degree relatives for burn coverage or bone chips removed during another procedure. The tissue is then processed by a tissue bank before it reaches the operating room.

Where Allografts Are Used

The range of allograft applications is broad. The most common categories give a sense of just how versatile donor tissue can be.

Bone

Bone allografts are workhorses in orthopedic and dental surgery. They come as small chips, ground-up powder, or large structural segments, depending on the job. In pediatric foot surgery, small structural bone allografts have been shown to heal at about the same rate as autografts harvested from the hip, with both groups reaching union in just over seven weeks on average.² At the other extreme, massive structural allografts are used in revision hip replacement when there is a large defect in the socket. A meta-analysis of 28 studies found an overall implant failure rate of about 16% at eight years, though the rate varied considerably by technique, dropping to around 12% when the graft was paired with a reinforcement device and rising to 30% with a cemented cup.³

Ligaments and Tendons

Anterior cruciate ligament (ACL) reconstruction is one of the best-studied allograft procedures. The surgeon threads a replacement tendon through tunnels drilled in the knee bones to stand in for the torn ACL. Using donor tissue means no second harvest site, less post-operative pain, and a shorter initial surgical time. The catch is that allograft tendons incorporate more slowly than autografts. Animal studies show that this gap narrows over the first year but never fully disappears in the early healing window.⁴ Paradoxically, the quicker recovery from an allograft procedure can tempt patients back to sport before the graft is biologically ready, increasing retear risk.

Clinical failure rates reflect this pattern. A systematic review found that graft failure in nonirradiated allografts ranged from 0% to about 27%, compared with 0% to about 9% for autografts, with the gap most pronounced in younger patients. Among people 21 and under, the allograft failure rate was roughly four times higher than autograft; in those over 22, the difference shrank considerably.⁵ A separate study using bone-patellar tendon-bone grafts reported five-year graft survival of about 91% for autografts versus 77% for allografts, with allograft use independently predicting failure and lower rates of return to preinjury sport.⁶ This is why many surgeons now lean toward autograft for young, highly active patients and reserve allografts for older or less active individuals, revision cases, or multi-ligament reconstructions where harvesting enough of the patient’s own tissue is impractical.

Skin

For major burns, skin allografts serve as a biological dressing that buys time while the patient’s own skin is prepared for permanent grafting. Skin allografts are considered the gold standard temporary coverage for burns when the patient simply does not have enough unburned skin to cover all the damaged areas at once.⁷ The allograft reduces microbial contamination, improves the blood supply to the wound bed, and promotes healthy granulation tissue, all of which help permanent autografts take hold later. Freshly donated skin from living relatives performs particularly well, likely because it arrives at maximum viability without requiring preservation steps.⁸ The allograft is eventually rejected and replaced, but by then it has served its purpose.

Corneas

Corneal transplantation is the oldest and most successful form of solid-organ allograft, performed in humans for over a century. The eye enjoys a unique immune privilege: because the cornea has no blood vessels and the front chamber of the eye actively suppresses immune responses, corneal allografts achieve long-term survival in anywhere from 50% to over 90% of recipients without the heavy immunosuppressive drug regimens required for, say, a transplanted kidney.⁹ By comparison, a skin allograft placed across the same genetic mismatch would be rejected virtually 100% of the time. This makes the cornea an outlier in transplant immunology and a major reason why corneal transplants are so common worldwide.¹⁰

Heart Valves

Donor heart valves, often called homografts, are used to replace diseased valves, especially in children and young adults where a mechanical valve or bioprosthetic valve may be less ideal. These allografts gradually wear out over time. One study examining explanted valves found that pulmonary homografts lasted roughly 9.5 years on average before needing replacement, while aortic homografts lasted about 4.3 years.¹¹ That limited lifespan is a known trade-off, but for certain patients the biological compatibility and growth potential of a homograft outweigh the durability of a mechanical alternative.

How Allograft Tissue Is Processed and Sterilized

Between recovery from the donor and implantation in the recipient, allograft tissue goes through a chain of processing steps. The goal is to reduce the risk of disease transmission and immune reaction while preserving as much of the tissue’s biological usefulness as possible. These two goals are in tension: more aggressive sterilization kills more pathogens but also damages the proteins and growth factors that help the graft heal.

Gamma irradiation is the most widely used sterilization method for biological tissues.¹² The radiation dose matters: higher doses kill more organisms but degrade collagen and reduce levels of growth factors like TGF-β and bFGF. Research on amnion grafts showed that even though gamma irradiation at 15 or 25 kGy significantly reduced growth factor levels, enough remained to support tissue healing.¹³ Ethylene oxide gas is another option, used at low temperatures when radiation might be too damaging for a particular tissue type.¹⁴

Preservation methods include deep freezing (gradually cooling to −80°C for long-term storage) and freeze-drying (vacuum-drying at very low temperatures so the tissue can be stored at room temperature). Each method has trade-offs in shelf life, shipping convenience, and how well the tissue retains its mechanical and biological properties.

Donor Screening and Safety

Disease transmission from allograft tissue is rare, but the consequences can be severe. After two multistate outbreaks of tuberculosis traced back to viable bone allografts, the American Association of Tissue Banks developed evidence-based screening criteria to reduce TB transmission risk. The criteria consider both exposure factors (where a donor was born, whether they were incarcerated or homeless, workplace exposures) and reactivation factors (kidney or liver disease, history of transplantation, immunosuppressive medications, age).¹⁵ Donors with viable-cell tissues face a stricter subset of these criteria, since living cells can harbor organisms that processed, acellular tissue cannot.

Beyond TB, tissue banks screen donors for HIV, hepatitis B and C, syphilis, and other transmissible infections, using a combination of blood tests and medical-history review. Regulatory oversight in the United States has been handled by the FDA since 1997, which classifies allograft tissue as “human cells, tissues, and cellular and tissue-based products” (HCT/Ps). Tissue banks can also undergo voluntary accreditation by the AATB, which sets additional standards for quality and safety.¹⁶

The Immune Response to Allografts

When your body encounters tissue from another person, your immune system may recognize it as foreign and mount a rejection response. The main driver is a set of surface proteins called human leukocyte antigens (HLA). The greater the mismatch between donor and recipient HLA, the higher the risk of rejection. In organ transplants like kidneys, HLA mismatches prolong the wait for a suitable donor, reduce graft survival, and increase mortality.¹⁷

For many tissue allografts, though, rejection is a far smaller concern than it is for solid organs. Bone, tendon, and cartilage grafts are typically processed to remove most or all living donor cells. Without cells presenting foreign HLA molecules on their surface, the immune system has much less to react to. This is why you do not need to take immunosuppressive drugs after receiving a bone allograft in your knee, whereas a kidney transplant patient takes them for life. Corneal grafts occupy a middle ground: they contain living cells, but the eye’s immune privilege protects them.

Decellularized Allografts and Acellular Dermal Matrices

One of the biggest advances in allograft technology is decellularization, the process of stripping all cellular material from a tissue while leaving the underlying scaffold of collagen, elastin, and other structural proteins intact. The result is called an acellular dermal matrix (ADM) when made from skin, or more generally a decellularized allograft. This scaffold gets incorporated into your own tissue over time and is gradually replaced by your body’s own collagen, supporting healing and reducing scar formation.¹⁸

The method used to decellularize matters a great deal. Research comparing different protocols has shown that gentler, low-detergent approaches preserve more of the key structural proteins (collagen IV, elastin, laminin) and support better cell growth and tissue integration when implanted, while harsher methods strip the scaffold too aggressively.¹⁹ ADMs are now widely used in breast reconstruction, abdominal wall repair, and gum tissue regeneration. A preclinical study on massive bone allografts found that decellularized grafts showed significantly more bone remodeling, more bone-forming cell activity, and deeper new bone growth compared with standard allografts three months after implantation.²⁰

What Allografts Cost Compared to Alternatives

Cost is a real factor in graft selection, and the answer depends on the procedure. For ACL reconstruction, allografts tend to be more expensive than autografts because the tissue itself carries a procurement and processing fee. One study found that the mean total hospital cost for soft-tissue ACL reconstruction was about $4,070 for autograft versus $5,200 for allograft, a difference driven almost entirely by the cost of supplies (the graft tissue).²¹ A cost-effectiveness analysis went further, concluding that hamstring autograft was both the least expensive and most effective graft choice for the average ACL patient, while allograft was the most expensive and least effective.²²

That picture flips in nerve repair. For peripheral nerve injuries, an analysis found that using a processed nerve allograft actually saved money compared with autograft (about $12,700 versus $14,000), largely because autograft nerve repair requires a second surgical site and longer operative time. The allograft also had a modestly higher probability of meaningful recovery.²³ The lesson is that cost comparisons are procedure-specific, and a blanket statement that one graft type is “cheaper” does not hold.

Synthetic bone substitutes offer unlimited supply and easy sterilization, but they have their own limitations. They tend to be brittle, resorb at unpredictable rates, and perform poorly in certain clinical conditions.²⁴ For procedures requiring biological integration and structural support, allografts often remain the preferred middle ground between autografts and synthetics.

What Patients Should Know Before Consent

If your surgeon recommends an allograft, you should expect a clear preoperative conversation about what the tissue is, where it comes from, and what the alternatives are. That does not always happen. An audit at one hospital found that only about 38% of patients undergoing elective orthopedic surgery with allograft had adequate documentation of consent for allograft use. Even after the hospital implemented improvements, the figure rose only to 56%.²⁵ There was no correlation between how often a surgeon used allografts and how well they documented consent, suggesting the gap is systemic rather than tied to inexperience.

Before surgery, it is reasonable to ask your surgeon whether the graft will be from a donor or from your own body, what the expected failure rate is for each option in your specific situation, and how the donor tissue was screened and processed. For ACL surgery in particular, age and activity level strongly influence which graft type offers the best long-term outcome, so understanding the trade-offs is worth the conversation. Religious or cultural beliefs about receiving human tissue from a deceased donor also factor in for some patients, and bringing those up early avoids surprises in the operating room.

Peripheral Nerve Allografts

While bone and tendon allografts get most of the attention, processed nerve allografts represent a growing niche. When a nerve is severed or a segment is lost, the gap needs to be bridged with something that nerve fibers can grow through. Traditionally, a piece of sensory nerve is harvested from somewhere less critical on the patient’s body, but this sacrifices sensation at the donor site and adds operative time. Decellularized nerve allografts preserve the tube-like structure that nerve fibers follow while removing all donor cells, giving regenerating axons a ready-made highway without the second surgery. As noted in the cost section, outcomes for nerve allografts appear comparable to autografts for many gap lengths, and the total cost can actually be lower because the procedure is simpler. This is one area where allografts are displacing autografts not as a compromise but as a genuinely competitive first choice.